@article{de6f4e7844784f8ebfaf814281a4defa,
title = "A Novel Transgenic Mouse for Gene-Targeting Within Cells That Express Corticotropin-Releasing Factor",
abstract = "Corticotropin-releasing factor (CRF) orchestrates the mammalian endocrine, autonomic, and behavioral stress response and has been implicated in the pathophysiology of illnesses ranging from irritable bowel syndrome to mood and anxiety disorders. CRF is produced and released from a variety of cell types, making it difficult to distinguish the specific role of CRF from other neurotransmitters with which it colocalizes. To clarify the basic biology of the CRF neuron, we must be able to manipulate selectively CRFergic cells. Here we describe a novel transgenic mouse using 3.0 kb of the CRF promoter to drive expression of Cre-recombinase (CRFp3.0Cre). Crossing CRFp3.0Cre with a fluorescent reporter strain results in Cre-dependent green fluorescent protein expression within CRF-producing cells. Thus, CRF cells can be identified for single-cell polymerase chain reaction and electrophysiological procedures. Furthermore, the CRFp3.0Cre transgenic can be combined with other available mouse strains containing a {"}floxed{"} gene of interest to allow unparalleled detailed analysis of the CRF system.",
keywords = "Amygdala, corticotropin releasing factor, Cre-recombinase, lentiviral vector, promoter specificity, transgenic",
author = "Martin, {Elizabeth I.} and Ressler, {Kerry J.} and Jasnow, {Aaron M.} and Joanna Dabrowska and Rimi Hazra and Rainnie, {Donald G.} and Nemeroff, {Charles B.} and Owens, {Michael J.}",
note = "Funding Information: Dr. Owens has research grants from the National Institutes of Health , Eli Lilly , Pfizer , GlaxoSmithKline , Lundbeck , Cyberonics , Ortho-McNeil Janssen , AstraZeneca , Dainippon Sumitomo . He is a consultant with H. Lundbeck A/S, and has received honorarium with Eli Lilly . Dr. Owens has a patent titled “A Method to Estimate Transporter Occupancy.” Funding Information: The following funding institutions and agencies provided support for this work: National Institutes of Health MH-42088 , MH079667A , MH-541380 , MH-77083 , MH-69056 , MH-58922 , MH-39415 , DA019624 , and RR-00039 ; Burroughs Wellcome Fund . Funding Information: Dr. Ressler has received awards and/or funding support from Lundbeck , Burroughs Wellcome Foundation , Pfizer , the National Alliance for Research on Schizophrenia and Depression (NARSAD) , the National Institute of Mental Health (NIMH) , and the National Institute on Drug Abuse (NIDA) and has a consulting agreement with Tikvah Therapeutics for N-methyl-D-aspartate-based therapeutics. Funding Information: Dr. Rainnie has received research grants from NIMH , NARSAD , and the Whitehall Foundation (Grant Nos. MH069852 and MH072908 ). ",
year = "2010",
month = jun,
day = "15",
doi = "10.1016/j.biopsych.2010.01.026",
language = "English (US)",
volume = "67",
pages = "1212--1216",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "12",
}